Serina Therapeutics (NYSEAMERICAN:SER) Director Acquires $20,101.95 in Stock

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Director Richard Peter Marshall acquired 12,183 shares of Serina Therapeutics stock in a transaction dated Tuesday, May 19th. The shares were purchased at an average price of $1.65 per share, with a total value of $20,101.95. Following the acquisition, the director owned 12,183 shares of the company’s stock, valued at approximately $20,101.95. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Serina Therapeutics Trading Up 4.9%

Shares of NYSEAMERICAN:SER traded up $0.09 during trading on Friday, reaching $1.98. 194,287 shares of the stock were exchanged, compared to its average volume of 2,913,021. Serina Therapeutics, Inc. has a 12 month low of $1.22 and a 12 month high of $7.92. The company has a market cap of $29.70 million, a price-to-earnings ratio of -0.99 and a beta of 1.15. The company’s 50-day moving average is $1.94. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.18 and a current ratio of 4.18.

Serina Therapeutics (NYSEAMERICAN:SER) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.58) earnings per share (EPS) for the quarter.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.